Related Experiment Video
Updated: Aug 24, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.6K
Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized
Nazha Hamdani1,2,3,4, Sarah Costantino5, Andreas Mügge2,3
1Institute of Physiology, Ruhr University, Bochum, Germany.
European Heart Journal
|October 25, 2022
Summary
Heart failure with preserved ejection fraction (HFpEF) is a major unmet need. Epigenetic modifications offer novel diagnostic and therapeutic targets for personalized HFpEF management.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Genetics
Background:
- Heart failure with preserved ejection fraction (HFpEF) is the most common type of heart failure, disproportionately affecting women and posing significant healthcare challenges.
- The heterogeneity of HFpEF phenotypes complicates diagnosis and treatment, highlighting the urgent need for novel therapeutic strategies.
- Epigenetic modifications, influenced by environmental factors, play a crucial role in the pathogenesis of HFpEF by altering gene expression related to oxidative stress, inflammation, and cardiac remodeling.
Approach:
- This review explores the role of epigenetics in HFpEF, focusing on DNA, histone, and non-coding RNA modifications.
- It discusses the potential of epigenetic biomarkers, identified through advanced sequencing and computational methods, for personalized HFpEF diagnosis and monitoring.
- The potential of 'epidrugs' targeting epigenetic mechanisms to reverse pathological transcriptional changes in HFpEF is also examined.
Key Points:
- Epigenetic alterations are central to the development of HFpEF, linking environmental exposures to maladaptive cardiac changes.
- Epigenetic biomarkers offer a dynamic and reversible alternative to genetic markers, reflecting lifestyle and environmental impacts.
- Emerging epidrugs demonstrate promise in preventing or reversing the molecular pathways driving HFpEF.
Conclusions:
- Clinical epigenetics represents a promising frontier for the personalized management of HFpEF.
- Harnessing epigenetic insights can lead to novel diagnostic tools and targeted therapies for this challenging cardiovascular condition.
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:29Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:26Heart Failure III: Clinical Manifestations
38
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
38
01:27Heart Failure I: Introduction
43
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
43
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K